William Blair Assumes Xenon Pharmaceuticals (XENE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts XENE Hot Sheet
Price: $36.57 -2.66%
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 26 | Down: 19 | New: 65
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 26 | Down: 19 | New: 65
Join SI Premium – FREE
William Blair analyst Myles Minter assumes coverage on Xenon Pharmaceuticals (NASDAQ: XENE) with a Outperform rating.
For an analyst ratings summary and ratings history on Xenon Pharmaceuticals click here. For more ratings news on Xenon Pharmaceuticals click here.
Shares of Xenon Pharmaceuticals closed at $37.59 yesterday.
You May Also Be Interested In
- Freedom Broker Starts Delek US (DK) at Hold
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Barclays Starts Bausch & Lomb Corp. (BLCO) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
